Skip to content
Evigrade
CriticalSystemic decongestant, sympathomimetic×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative

Updated · Methodology

Mechanism

Pseudoephedrine constricts blood vessels by acting on alpha-1 adrenergic receptors. It also works as an indirect sympathomimetic: sympathetic nerve fibres take it up, and it displaces norepinephrine from their vesicles (pseudoephedrine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Monoamine oxidase (MAO) inhibitors, tranylcypromine included, increase catecholamine release and may prolong and intensify the vasopressor and cardiac stimulant effects of pseudoephedrine (pseudoephedrine SmPC, AEMPS). Tranylcypromine inhibits MAO A and B irreversibly, and full enzyme activity returns only 3–5 days after the last dose (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine label, US Food and Drug Administration, FDA).

Symptoms

A monoamine oxidase (MAO) inhibitor combined with pseudoephedrine can cause severe hypertension, hyperpyrexia and headache (pseudoephedrine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US tranylcypromine label also names a risk of intracerebral haemorrhage with sympathomimetics (tranylcypromine label, US Food and Drug Administration, FDA). A hypertensive crisis during tranylcypromine treatment may come with a fast heart rate, facial flushing, headache (especially at the back of the head), neck stiffness, nausea, vomiting and sensitivity to light (tranylcypromine SmPC, AEMPS). In a hypertensive emergency, blood pressure is severely raised (for example, above 180/120 mm Hg) and there are signs of organ damage. Sweating, dilated pupils, shortness of breath, confusion, constricting chest pain and seizures may occur (tranylcypromine FDA label). Pseudoephedrine alone, at the usual dose, can raise blood pressure, speed up the heart rate and stimulate the central nervous system (pseudoephedrine SmPC, AEMPS).

Management

The combination is contraindicated. The pseudoephedrine summary of product characteristics (SmPC) contraindicates all monoamine oxidase inhibitors (MAOIs) and gives tranylcypromine as an example (pseudoephedrine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The SmPC of its combination with desloratadine carries the same contraindication because of pseudoephedrine (European Medicines Agency, EMA). The US tranylcypromine label names pseudoephedrine among contraindicated drugs. The US label of over-the-counter pseudoephedrine tells people not to take it with a prescription MAOI (tranylcypromine and pseudoephedrine labels, US Food and Drug Administration, FDA). The Spanish tranylcypromine SmPC contraindicates indirect sympathomimetics in nasal, cough and cold remedies. It places pseudoephedrine among direct sympathomimetics and advises avoiding these combinations because of their effect on blood pressure (tranylcypromine SmPC, AEMPS). Pseudoephedrine is not taken during tranylcypromine treatment or for 2 weeks after stopping it (pseudoephedrine SmPC, AEMPS; desloratadine/pseudoephedrine SmPC, EMA; over-the-counter pseudoephedrine FDA label). The interactions section of the Spanish pseudoephedrine SmPC gives 15 days (pseudoephedrine SmPC, AEMPS). The tranylcypromine SmPC recommends a 14-day break after stopping tranylcypromine before starting an incompatible drug (tranylcypromine SmPC, AEMPS). Start tranylcypromine no earlier than 4–5 half-lives of a contraindicated drug and its active metabolites after that drug is stopped (tranylcypromine FDA label). Warn people treated with tranylcypromine that cold and nasal remedies may contain sympathomimetics. They should take over-the-counter medicines or dietary supplements only after advice on possible interactions (tranylcypromine SmPC, AEMPS, and FDA label). Measure blood pressure before starting tranylcypromine and monitor it closely during treatment (tranylcypromine FDA label). Stop pseudoephedrine if blood pressure rises or if a fast heart rate, palpitations, arrhythmia, nausea or headache appear (pseudoephedrine SmPC, AEMPS). At early signs of a hypertensive crisis, interrupt treatment and assess the patient at once. Stop tranylcypromine and any other possible cause of the crisis at once. If blood pressure is severely raised (for example, above 180/120 mm Hg) and there are signs of organ damage, lower it immediately (tranylcypromine FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Pseudoephedrine

Other interactions with Tranylcypromine